Mor, I J <br/><br/>
Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy.  [electronic resource] 

 -  Diseases of the colon and rectum  Aug 2008 
 - 1202-7; discussion 1207-10 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1530-0358 
<br/><br/><label>Standard No.: </label>10.1007/s10350-008-9364-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Case-Control Studies<br/>Chi-Square Distribution<br/>Colitis, Ulcerative--drug therapy<br/>Combined Modality Therapy<br/>Female<br/>Gastrointestinal Agents--adverse effects<br/>Humans<br/>Infliximab<br/>Logistic Models<br/>Male<br/>Postoperative Complications--etiology<br/>Proctocolectomy, Restorative<br/>Retrospective Studies<br/>Risk<br/>Statistics, Nonparametric<br/>Treatment Outcome